Many drugs are under development to determine the extent of effectiveness against Coronavirus. Most of them are already subjected to the final stages of clinical trials and are showing promising results so far.
Remdesivir is a strong contender. There are already high demands as it is even though no final findings have been released and mass production still has not commenced. In the best case scenario that it proves to be safe and effective and deemed satisfactory for distribution, demands will certainly be a lot of times larger by then.
By means of artificial intelligence, research teams are now getting new ideas on engineering existing drugs with anti-Covid properties. The results generated by the AI helped uncover formulas for patented drugs that will pave way for less costly production methods of new medicines by using readily available raw materials. AI has been helpful in a lot of ways to handle the pandemic. CAIAC is an AI that detected hotspots and patterns garnered from patient information and diagnostic data.
Patent protection gives a manufacturer exclusive rights to produce and distribute a drug product with a minimum length of 20 years. Only then will other companies be able to make the same drug when the patent expires. This creates an advantage to the first company in terms of sales, recognition, and trust. But with the virus affecting the entire world, there is no room for that now.
The University of Michigan chemists sought help from Synthia, a commercial drug synthesis AI program, which can generate many options far beyond the capacity of the human mind.
The team ravaged the available literature for formulations of the drugs being used to combat Covid-19, and the AI was programmed to render new methods of synthesis filtered only to show those that can be made using readily available materials and also yield large amounts.
Results showed viable solutions for 11 drug substances out of 12, Remdesivir being the exception. Umifenovir had four ways to be engineered with one using cheaper materials than the existing formulation. The synthesis methods have been patented by the team not for capitalism purposes, but to limit the number of companies that will be provided with materials and regulate prices.
Clinical trials will then be immediately conducted after successful production.